How effective are Apremilast tablets? Feedback and evaluation from patients after use

Apremilast is an oral small molecule phosphodiesterase 4 (PDE4) inhibitor, mainly used to treat psoriasis (Psoriasis) and psoriatic arthritis (Psoriatic Arthritis) and other inflammatory diseases. Since its launch, Apremilast has attracted the attention of many patients and clinicians due to its unique mechanism of action and oral administration method. This article will introduce in detail the therapeutic effect of the drug, patient feedback, advantages and disadvantages, etc., to help patients fully understand the true effect of Apremilast.

First of all, the therapeutic effect of Apremilast has been relatively stable in clinical trials. By inhibiting PDE4, it regulates the release of inflammatory factors and reduces inflammatory responses, thereby improving the symptoms of psoriasis and psoriatic arthritis. A large amount of clinical data shows that many patients who take Apremilast have achieved significant improvement in skin symptoms in about 12 weeks, especially the reduction of erythema, scales and itching. For patients with psoriatic arthritis, Apremilast can also effectively relieve joint swelling and pain, improve joint function and quality of life. Compared with traditional immunosuppressants, Apremilast has milder side effects and does not require injections, making it easier for patients to take it for a long time.

Patients’ real-life feedback also provides an important reference for the efficacy of Apremilast. After receiving Apremilast treatment, many patients report that their skin symptoms have improved significantly and their quality of life has greatly improved. Some patients say that oral apremilast avoids the inconvenience and pain of injectable drugs and enhances treatment compliance. In addition, Apremilast is particularly suitable for use in long-term outpatient management for patients with mild to moderate psoriasis because it is relatively safe and does not require frequent monitoring of liver and kidney function and other indicators.

However, some patients report that the efficacy of Apremilast is slow to take effect, and some patients do not see significant improvement in the first few weeks and need to persist in taking the drug to feel the effect. In addition, a small number of patients may experience gastrointestinal reactions, such as diarrhea, nausea, etc. These adverse reactions are generally more obvious in the early stages of medication and gradually ease as the body adapts. For some patients with severe psoriasis, Apremilast monotherapy may have limited effectiveness and needs to be used in combination with other treatments.

As a new oral targeted drug, Apremilast has shown good safety and moderate efficacy in the treatment of psoriasis and psoriatic arthritis. It provides patients with an alternative to injectable biologics and is particularly suitable for patients who wish to avoid the side effects of injections or traditional immunosuppression. Patients should follow the doctor's instructions during use, wait patiently for the efficacy to appear, and provide timely feedback on adverse reactions. The doctor will also adjust the treatment plan according to the specific situation.

In summary, the true effectiveness of Apremilast varies among individual patients, but overall reviews are positive. It not only improves the skin and joint symptoms of many patients, but also improves their quality of life and medication compliance. As clinical experience accumulates, Apremilast is expected to become an important treatment option in the management of psoriasis and psoriatic arthritis. Good patient communication and cooperation during treatment will help maximize the therapeutic potential of the drug.

Reference materials:https://go.drugbank.com/drugs/DB05676